TheEdgeResearch
Home / Stocks / CLVLF

Clinuvel Pharmaceuticals Limited (CLVLF)

OTC Healthcare Biotechnology
$4.95 ▲ +0.00%
Market Cap
$249.9M
Sector
Healthcare
Industry
Biotechnology
Beta
0.57
52-Wk Range
4.95-8.45
CEO
Philippe Jacques Wolgen
Country
AU
Currency
USD

Clinuvel Pharmaceuticals Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Melbourne, VIC, AU. The stock last traded at $4.95, up 0.00% on the session, giving a market capitalisation of $249.9M. On trailing twelve-month figures it carries a trailing P/E of 10.51, a net margin of 36.1%. Its beta of 0.57 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
10.51
Price / Sales
3.84
Price / Book
1.30
EV / EBITDA
8.25
Gross margin
43.1%
Operating margin
43.1%
Net margin
36.1%
Return on equity
—
Debt / equity
0.01
Current ratio
14.81
Dividend yield
0.7%
Payout ratio
7.4%
Company profile
Exchange
Other OTC
Employees
109
IPO date
2009-02-13
Headquarters
Melbourne, VIC, AU
About Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of treatments for patients battling genetic, metabolic, and life-threatening conditions. Its reach extends across Australia, Europe, the United States, Switzerland, and other global markets. The company's flagship drug, SCENESSE, serves as a systemic photoprotective treatment intended to prevent phototoxicity in adult patients diagnosed with erythropoietic protoporphyria (EPP). Clinuvel's development pipeline includes CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which promotes prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Additionally, Clinuvel Pharmaceuticals has partnered with HK Winhealth Pharma Group Co. Limited for a named patient program in the People's Republic of China, enabling the treatment of EPP patients with SCENESSE. Founded in 1987, the company's corporate headquarters are situated in Melbourne, Australia.

More research on CLVLF
CLVLF technical analysis CLVLF TheEdge Score Compare against peers
Open full interactive analysis & DCF →